Slide 1: Corporate Deck August 2025
NYSE:VNRX Corporate Deck August 2025 Property of Volition© 2025 Slide 1
Slide 2: Forward Looking Statements and Disclaimer
Forward Looking Statements and Disclaimer Statements in this document may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncer
Slide 3: Our mission is to save lives and improve outcomes
Our mission is to save lives and improve outcomes for millions of people and animals worldwide. Property of Volition© 2025 Slide 3
Slide 4: At-a-Glance
At-a-Glance VolitionRx Our Focus Commercial Multi-National (NYSE: VNRX) • Advancing low-cost, Validation • Diagnostics early detection and • Commercial • ~80 employees (epigenetics) treatment monitoring launches worldwide • Commercial Stage tests in animal health • 27,000 sq ft lab and (2022-2024) p
Slide 5: Powered by Nu.Q®: Broad Patent Protection for Products
Powered by Nu.Q®: Broad Patent Protection for Products 1. Nu.Q® Discover H3.1 RUO Kit 1. Lung Cancer Screening 1. Diseases 1. Canine Cancer Test associated with 2. Nu.Q® Discover H3R8Cit 2. Lung Cancer Prototype Kit 2. Wellness Test i10 NETosis Prognostication/ Aid to Treatment Selection 3. Nu.Q® Di
Slide 6: Investment Highlights
Investment Highlights Vet Commercial Progress Large Unmet Needs • Nu.Q® Vet Cancer test now available in over 20 countries • Lung Cancer – screening, prognostics and MRD • Sold ~120,000 tests and test components 2024 represent a $4B opportunity. MCED Liquid Biopsy ~$20B • Received $23 million in upf
Slide 7: Executive Team
Executive Team Cameron Reynolds MBA, Terig Hughes Gaetan Michel PhD Louise Batchelor Andrew Retter Jake Micallef, PhD President & Group CEO Group CFO COO Group CMO and Chief Medical Officer CSO Comm. Officer Gael Forterre, MBA Jasmine Kway PhD Tom Butera DVM Nick Plummer, Rodney Rootsaert CCO CEO, V
Slide 8: What sets us apart?
What sets us apart? • Our tests are simple, low-cost accessible routine blood tests • Platform agnostic, can be adapted to any diagnostic workflow • Manual, Reference Lab, Specialist Lab and Point of Care Six Hours 45 minutes <10 minutes <15 minutes • Our expanding Intellectual Property portfolio •
Slide 9: The Science Behind Our Technologies
The Science Behind Our Technologies cfDNA Profiles Vary Across Disease and Cell Death Mechanisms Apoptosis Length of Plasma Derived DNA Cancer Sepsis NETs Data on file Circulating nucleosome levels increase as they are released faster than they can be removed Property of Volition© 2025 Slide 9
Slide 10: Licensing Portfolio: Platform stable, reproducible
Licensing Portfolio: Platform stable, reproducible Application Proof of Concept Viability Validation Licensed Animal Canine Cancer Screening Launched Canine Cancer Monitoring Feline Cancer Automated test Signed with Fuji Sepsis Data room available Cancer Data room available Lung Cancer Screening Dat
Slide 11: Go-to-Market Strategy
Go-to-Market Strategy R&D • R&D conducted by Volition and its research partners • Monetize IP through commercial contracts with upfront payments, milestone payments, royalties and sales of key components Non-exclusive licensing and partnering criteria: ✓ Broad geographic reach ✓ Large installed base
Slide 12: Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test Property of Volition Veterinary Diagnostics Development© 2025 Slide 12
Slide 13: Nu.Q® Vet
Nu.Q® Vet • Licensed to two of the largest veterinary service companies world-wide • Available via reference labs and at point-of-care in-clinic exclusively with Antech • Nu Q® Vet Cancer Test developed with the goal of providing an accessible and affordable screening test to aid in early cancer det
Slide 14: Now Sold ~120,000
Now Sold ~ 120,000 available in Nu.Q® Vet Cancer 100% 20+ Tests & Test increase in countries and Components in tests sold growing! 2024 2024 vs 2023 Property of Volition Veterinary Diagnostics Development© 2025 Slide 14
Slide 15: Licensing & Supply Agreements to-date
Licensing & Supply Agreements to-date • Launched with IDEXX in the U.S • Launched in U.S. / Aus Jan ‘23 /HK/Singapore/ some EU • Launched in UK & Ireland Nov ‘23 countries April ‘24 • Launched July ‘24 • Launched in Portugal • Launched in Nov ‘22 Singapore Nov ‘23 • Launched in Taiwan Nov ‘23 • Laun
Slide 16: Nu.Q® exclusively available in-house with Antech
Nu.Q® exclusively available in-house with Exclusive Element i+ in-house analyzer licensing partnershjp with Antech $10M upfront and $13M milestone payments received to-date. $5M milestone payment linked to use in felines remaining Launched April 2024 Ongoing revenue from the purchase of kits and key
Slide 17: Extended agreement with IDS
Extended agreement with • First ever Nu.Q® Vet Cancer Test Automation ! • Immunodiagnostic Systems (IDS) i10® automated analyzer platform • Final validation and verification of the automated platform for canine cancer screening, with the aim of launching in the summer of 2025 • Enable a more rapid t
Slide 18: Pre-Analytics for Cats: Nu.Q® products for cats
Pre- Analytics for Cats: an essential step in the development of Nu.Q® products for cats, our third species • This is the first study to report the detection of nucleosomes in cats, previously nucleosome levels have been shown to increase in dogs and humans in certain disease states, including cance
Slide 19: Targeting Epi-Drug and Anti-NETs
Targeting Epi-Drug and Anti-NETs drug developers and scientists’ access to a range of state-of-the-art assays for rapid epigenetic profiling Property of Volition© 2025 Slide 19
Slide 20: Two “firsts” in 2025 for Nu.Q® Discover
Two “firsts” in 2025 for Nu.Q® Discover • First commercial project utilising high-throughput NETs model • First human clinical study sponsored by a pharmaceutical company • Revenue increasing; targeting 100% growth in 2025 Property of Volition© 2025 Slide 20
Slide 21: Licensing Portfolio
Licensing Portfolio Property of Volition© 2025 Slide 21
Slide 22: Property of Volition © 2025 Slide 22
Property of Volition© 2025 Slide 22
Slide 23: Low-cost, routine and accessible tests
• Low-cost, routine and accessible tests to help detect and monitor disease progression and aid treatment selection Property of Volition© 2025 Slide 23
Slide 24: Potential applications of a blood test in lung cancer
Potential applications of a blood test in lung cancer: Nu.Q® addresses all five Property of Volition© 2025 Slide 24
Slide 25: Study Overviews
Study Overviews • Range of studies from prospective and retrospective, blinded, longitudinal studies of lung cancer. • Cohort sizes – ranging from 70 to 1000+ patients. • Covering detection of lung cancer at diagnosis and during treatment • KEY Outcome measures to demonstrate CLINICAL UTILITY (corre
Slide 26: Studies at Centers of Excellence
Studies at Centers of Excellence Study Country Cohort Size Key Results Status NucleoCircan France 628 subjects • identify additional 23% of patients that have MRD over ctDNA alone Published • Supports clinical decision to continue first line treatment (-ve MRD) 319 LC or change treatment (+ve MRD) 3
Slide 27: Multi-Cancer Early Detection
Multi-Cancer Early Detection Property of Volition© 2025 Slide 27
Slide 28: Nu.Q® assay for cross-linked plasma cf-nucleosomes
Nu.Q® assay for cross-linked plasma cf- nucleosomes 10000 100 H3.1-nucleosomes (ng/mL) 80 1000 Crosslinked Sensitivity% 60 100 AUC=85.5% 40 10 20 1 0 0 20 40 60 80 100 C g O ea t o e al el ag l ta t O do rv er St no us Th a a yr ch s lo L B RC B L te LuHL va tic N a B nge l n c Du r tie in at y ar R
Slide 29: Proof of Concept: Potential Breakthrough Cancer Detection Method
Proof of Concept: Potential Breakthrough Cancer Detection Method1. • Novel wet chemistry pathway for ctDNA analysis • Discovered a completely new class of biomarkers that are invisible to current methods and demonstrated that they can be isolated as pure ctDNA • Identified hundreds of potential shor
Slide 30: Sepsis & Thrombosis
Sepsis & Thrombosis Property of Volition© 2025 Slide 30
Slide 31: Neutrophil Extracellular Traps (NETs)
Neutrophil Extracellular Traps (NETs) NETs: • are produced by ejecting chromosomal material out of the cell • catch and kill bacteria and viruses • can sterilize blood in minutes • first reported in 20041now the subject of > 5000 publications NEW review article published February 2025 (Dr. Retter, P
Slide 32: Increasing number of publications and interest in NETs
Increasing number of publications and interest in NETs Wang H, et al,; A bibliometric study. Medicine (Baltimore). 2023, https://doi.org/10.1097/MD.0000000000033806 Property of Volition© 2025 Slide 32
Slide 33: 1 in 5 deaths worldwide are associated with sepsis
1 in 5 deaths worldwide are associated with sepsis It’s the number 1... Almost 50 million cases resulting in Cause of death in Over 40% of 11 million deaths hospitals survivors suffer from long-term physical Over 40% of cases Cause for hospital or psychological are children under readmissions effec
Slide 34: Unmet Needs
Unmet Needs • Current diagnosis is empirical, multi-factorial and subjective. • CURRENT methods of assessment (SOFA and APACHE II) are both complex & slow. • Accepted need for improved diagnostics1. 1. Rudd et al. 2020 The Lancet doi: 10.1016/S0140-6736(19)32989-7. Property of Volition© 2025 Slide 3
Slide 35: Studies at Centers of Excellence
Studies at Centers of Excellence Study Country Description Cohort Size Status Amsterdam Netherlands Retrospective analysis of prospectively 1,713 intensive care Published. UMC collected cohort patients Multiple timepoints SISPCT Germany Retrospective analysis of prospectively 971 intensive care pati
Slide 36: Our focus…
Our focus… To develop a low-cost, routine test to stratify risk of sepsis particularly those at risk of progressing to multiple organ failure; in addition to monitoring the disease progression and response to treatment. • Data from several large-scale studies presented at ESICM LIVES 20241 • Manuscr
Slide 37: NETs involvement in multiple disease conditions
NETs involvement in multiple disease conditions DVT Thrombosis DIC Transplant Sepsis RA Autoimmune Diseases APS SIRS SLE BURNS TRAUMA Property of Volition© 2025 Slide 37
Slide 38: First Revenue recorded for CE-marked product H1 2025
First Revenue recorded for CE-marked product H1 2025 Clinical Applications Under Evaluation by Potential Clinical Applications in Discussion Centers of Excellence in Europe with Nu.Q® Burns NETs CE-marked test Distinction between SIRS and sepsis patients Sepsis patient management Sepsis patient mana
Slide 39: Financials
Financials Property of Volition© 2025 Slide 39
Slide 40: Financial Highlights as of 30th June 2025
Financial Highlights as of 30th June 2025 • Recorded approximately $0.4million revenue in Q2 2025, up 15% over the first half prior year. • Net cash used in operating activities $6.3 million for the quarter ; net cash used for the first half of 2025 down 30% . • Funding receipts in the second quarte
Slide 41: Covering Analysts
Covering Analysts FIRM ANALYST The Benchmark Company, LLC Bruce Jackson D. Boral Capital Jason Kolbert Zacks Steven Ralston CFA Freedom Capital Markets Ilya Zubkov H.C. Wainwright Yi Chen, Ph.D. CFA Property of Volition© 2025 Slide 41
Slide 42: Summary
Summary Property of Volition© 2025 Slide 42
Slide 43: Go-to-Market Strategy
Go-to-Market Strategy R&D • R&D conducted by Volition and its research partners • Monetize IP through commercial contracts with upfront payments, milestone payments, royalties and sales of key components Non-exclusive licensing and partnering criteria: ✓ Broad geographic reach ✓ Large installed base
Slide 44: Investment Summary
Investment Summary • Listed, commercial stage diagnostics company — developing low-cost, early detection and treatment monitoring diagnostics in human and animal health • Disease areas – global killers: Cancer, Sepsis; significant market opportunities • Human and Veterinary use cases: • Screening •
Slide 45: Questions?
Questions? Thank you for your interest in Volition. For more details, please visit www.volition.com Property of Volition© 2025 Slide 45